SCHEMBL7605049

SCHEMBL7605049

NCCP(=O)(O)CC(CCC(=O)O)C(=O)O

nearest known ligand 0.77

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GRM3 Q14832 2/20 0.73
FOLH1 Q04609 6/20 0.71
NAALAD2 Q9Y3Q0 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5483402 0.90 GRM3 (0.69) GRM3FOLH1NAALAD2
SCHEMBL20529841 0.87 GRM3 (0.81) GRM3FOLH1NAALAD2
SCHEMBL5051325 0.87 GRM3 (0.81) GRM3FOLH1NAALAD2
SCHEMBL7605302 0.86 FOLH1 (0.66) GRM3FOLH1NAALAD2
SCHEMBL1377500 0.86 GRM3 (0.79) GRM3FOLH1NAALAD2
SCHEMBL4135913 0.85 GRM3 (1.00) GRM3FOLH1NAALAD2
SCHEMBL10134655 0.83 FOLH1 (1.00) GRM3FOLH1NAALAD2
SCHEMBL15278193 0.83 FOLH1 (1.00) GRM3FOLH1NAALAD2
SCHEMBL12145013 0.83 GRM3 (0.73) GRM3FOLH1NAALAD2
SCHEMBL25500315 0.83 GRM3 (0.73) GRM3FOLH1NAALAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6413948-B1 CENTRAL NERVOUS SYSTEM DISORDERS GUILFORD PHARMACEUTICALS INC. 2002-07-02 US claimed
JP-2002514185-A 2002-05-14 JP claimed
US-6384022-B1 ENZYME INHIBITORS GUILFORD PHARMACEUTICALS INC. 2002-05-07 US claimed
JP-2001527084-A 2001-12-25 JP claimed
EP-1044206-A1 PRODRUGS OF NAALADASE INHIBITORS Guildford Pharmaceuticals Inc. (US) 2000-10-18 EP claimed
US-5977090-A Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors GUILFORD PHARMACEUTICALS INC. (US) 1999-11-02 US claimed
EP-0949922-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-10-20 EP claimed
WO-1999033848-B1 PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES GUILFORD PHARM INC (US) 1999-08-12 WO claimed
WO-1999033849-A1 PRODRUGS OF NAALADASE INHIBITORS GUILDFORD PHARMACEUTICALS INC. (US) 1999-07-08 WO claimed
WO-1998013044-A1 PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1998-04-02 WO claimed
US-6028216-A Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives GUILFORD PHARMACEUTICALS INC. (US) 2000-02-22 US disclosed
WO-1999033848-A1 PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES GUILFORD PHARMACEUTICALS INC. (US) 1999-07-08 WO disclosed